<unk> , sold under the brand name Aubagio, is the active metabolite of leflunomide.<unk>  was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010. 2-year results were positive. However, the subsequent TENERE head-to-head comparison trial reported that "although permanent discontinuations of therapy were substantially less common among MS patients who received<unk>  compared with interferon beta-1a, relapses were more common with<unk> ." The drug was approved for use in the United States in September 2012 and for use in the European Union in August 2013.
Teriflunomide
Tofacitinib
Etanercept
Leflunomide
Belatacept
Belimumab
Adalimumab
Abatacept